Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 1,701–1,720 of 17,937 drug recalls

Drug Recall Ongoing Historical recordClass I

Samurai-X Honey 6800, UPC 2 56891 27553 3.

by Pyramids Wholesale Inc.

Reason
Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/or tadalafil.
Recall initiated
March 19, 2024
Reported by FDA
May 1, 2024
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass I

Flower Power, CBD infused Female Enhancement, 59 ml bottle, UPC 0 678741 351646.

by Pyramids Wholesale Inc.

Reason
Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/or tadalafil.
Recall initiated
March 19, 2024
Reported by FDA
May 1, 2024
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass I

Weiner Boner Honey, 12g packet, 100% Organic Formula.

by Pyramids Wholesale Inc.

Reason
Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/or tadalafil.
Recall initiated
March 19, 2024
Reported by FDA
May 1, 2024
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass I

Spanish Fly 22K capsules, 2-count box, UPC 0 664979 979455

by Pyramids Wholesale Inc.

Reason
Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/or tadalafil.
Recall initiated
March 19, 2024
Reported by FDA
May 1, 2024
Distribution
Nationwide in the USA

View recall →

Drug Recall Completed Historical recordClass II

S.P.Labs, Thyroid, Full Strength, Rx only, For Manufacturing, Processing or Repackaging Use Only, Specialty Process Labs, Phoenix, AZ 85034, NDC 81305-500-01.

by Specialty Process Labs LLC

Reason
Failed Stability Specifications
Recall initiated
March 1, 2024
Reported by FDA
April 24, 2024
Distribution
U.S. Nationwide.

View recall →

Drug Recall Completed Historical recordClass II

Sterile Diluent, HUMALOG U-100 (insulin lispro injection), HUMULIN R U-100 REGULAR (insulin human injection), Insulin Lispro Injection u-100, 10 mL, Use ONLY with Insulins listed on carton, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285. NDC: 0002-0800-01

by Eli Lilly & Company

Reason
CGMP Deviations
Recall initiated
March 12, 2024
Reported by FDA
April 24, 2024
Distribution
Nationwide USA

View recall →

Drug Recall Terminated Historical recordClass III

Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactured by: Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-200-10

by Novitium Pharma LLC

Reason
Failed Impurities/Degradation Specifications
Recall initiated
March 25, 2024
Reported by FDA
April 24, 2024
Distribution
U.S. Nationwide

View recall →

Drug Recall Terminated Historical recordClass I

Vancomycin Hydrochloride for Oral Solution, USP, 250 mg per 5 mL, packaged as (a) 80 mL bottle, NDC 69238-2261-3; (b) 150 mL bottle, NDC 69238-2261-7; (c)300 mL bottle, NDC 69238-2261-5; Rx only, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807

by Amneal Pharmaceuticals of New York, LLC

Reason
Superpotent Drug: Due to overfilling of drug powder
Recall initiated
March 21, 2024
Reported by FDA
April 24, 2024
Distribution
Nationwide in the USA.

View recall →

Drug Recall Completed Historical recordClass III

NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03

by Esperion

Reason
Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.
Recall initiated
March 27, 2024
Reported by FDA
April 24, 2024
Distribution
Nationwide in the USA

View recall →

Drug Recall Completed Historical recordClass II

S.P Labs, Thyroid, USP, Rx only, For Manufacturing, Processing or Repackaging Use only, Specialty Process Labs, Phoenix, AZ, NDC #'s a) 81305-100-01, b)81305-100-02, c)81305-100-03

by Specialty Process Labs LLC

Reason
Failed Stability Specifications
Recall initiated
March 1, 2024
Reported by FDA
April 24, 2024
Distribution
U.S. Nationwide.

View recall →

Drug Recall Terminated Historical recordClass I

Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12.

by AvKARE

Reason
Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.
Recall initiated
March 28, 2024
Reported by FDA
April 24, 2024
Distribution
US Nationwide.

View recall →

Drug Recall Ongoing Historical recordClass I

Methocarbamol Injection, USP 1000mg/10mL, (100mg/mL), 10 mL Single-Dose Vial packed 25 vials per carton, Rx Only, Mfd. in India for: Eugia US LLC. E. Windsor, NJ 08520, NDC 55150-223-10

by Eugia US LLC

Reason
Presence of Particulate Matter
Recall initiated
February 15, 2024
Reported by FDA
April 17, 2024
Distribution
Nationwide in the USA

View recall →

Drug Recall Ongoing Historical recordClass II

Isotretinoin Capsules, USP 40mg, 30-count 3x10 blister packs per carton, Rx Only, Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054. Blister Pack NDC 0591-2436-45, Carton NDC 0591-2436-15

by Teva Pharmaceuticals USA, Inc

Reason
Superpotent Drug: The 3-month stability result for assay was found to be above specification limit
Recall initiated
March 28, 2024
Reported by FDA
April 17, 2024
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

Lansoprazole Delayed-Release Capsules USP, 15 mg, Acid reducer 24 Hour, Treats Frequent Heartburn, 14 capsules per bottle, Manufactured by: Natco Pharma Limited Kothur- 509 228, India, Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ. 08816. NDC 16571-742-41

by NATCO Pharma Limited

Reason
CGMP Deviations
Recall initiated
March 27, 2024
Reported by FDA
April 17, 2024
Distribution
Nationwide in the US

View recall →

Drug Recall Terminated Historical recordClass II

Rifampin Capsules USP, 300mg, 30-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India, NDC 6818-0659-06

by Lupin Pharmaceuticals Inc.

Reason
Subpotent Drug
Recall initiated
March 21, 2024
Reported by FDA
April 17, 2024
Distribution
Nationwide within the United States

View recall →

Drug Recall Ongoing Historical recordClass II

FentaNYL citrate, 10 mcg in 0.9% Sodium Chloride 1 mL Vial (10 mcg/mL), 1.5 mL Total Volume per Vial, Intravenous, Rx Only, Hospital/Office Use Only, SSM Health Care Corporation Outsourcing Facility, 1015 Bowles Ave, Fenton, MO 63026-2394. NDC: 60652-9010-1

by SSM Health Care St. Louis DBA SSM St. Clare Health Center

Reason
Lack of Assurance of Sterility: Firm did not perform process validation.
Recall initiated
February 29, 2024
Reported by FDA
April 10, 2024
Distribution
MO

View recall →

Drug Recall Ongoing Historical recordClass II

Phenylephrine HCl, 1000 mcg/10 mL, 10 mL Total Volume per syringe, Intravenous, Rx Only, Hospital/Office Use Only, This is a Compounded Drug - Not for Resale, SSM Health Care Corporation Outsourcing Facility, 1015 Bowles Ave, Fenton, MO 63026-2394. NDC: 60652-0104-1

by SSM Health Care St. Louis DBA SSM St. Clare Health Center

Reason
Lack of Assurance of Sterility: Firm did not perform process validation.
Recall initiated
February 29, 2024
Reported by FDA
April 10, 2024
Distribution
MO

View recall →

Drug Recall Terminated Historical recordClass III

Cyclophosphamide for Injection, USP, 1g/vial, Lyophilized, Single Dose Vial, Discard unused solution, Cytotoxic Agent, After Reconstitution: For direct intravenous injection or must be further diluted before intravenous infusion, Rx Only, Manufactured for: XGen Pharmaceuticals DJB, Inc., Big Flats, NY 14814, NDC # 39822-0255-01.

by X-Gen Pharmaceuticals Inc.

Reason
Labeling: Incorrect or missing Package Insert: There is an error on the Package Insert (PI), section 2.3, Preparation, Handling, and Administration. The concentration of the reconstituted product is listed as '20 mg per vial.' This information should read: '20 mg per mL'.
Recall initiated
April 2, 2024
Reported by FDA
April 10, 2024
Distribution
Nationwide in the US

View recall →

Drug Recall Terminated Historical recordClass III

Cyclophosphamide for Injection, USP, 500mg/vial, Lyophilized, Cytotoxic Agent, Single Dose Vial for Intravenous Use, Rx Only, Manufactured for: XGen Pharmaceuticals DJB, Inc. Big Flats, NY 14814, NDC # 39822-0250-01.

by X-Gen Pharmaceuticals Inc.

Reason
Labeling: Incorrect or missing Package Insert: There is an error on the Package Insert (PI), section 2.3, Preparation, Handling, and Administration. The concentration of the reconstituted product is listed as '20 mg per vial.' This information should read: '20 mg per mL'.
Recall initiated
April 2, 2024
Reported by FDA
April 10, 2024
Distribution
Nationwide in the US

View recall →

Drug Recall Ongoing Historical recordClass II

fentaNYL Citrate 2,500 mcg/50mL in Sterile Water, 50 mL CADD for Injection, IntegraDose Compounding Services, LLC, 719 Kasota Ave SE, Minneapolis, MN. NDC 71139-6030-1

by IntegraDose Compounding Services LLC

Reason
Lack of Assurance of Sterility: leaking bags
Recall initiated
March 22, 2024
Reported by FDA
April 10, 2024
Distribution
Nationwide within the U.S

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.